- Home
- EIC vs CDXC Comparison
EIC vs CDXC Comparison
Compare EIC & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- CDXC
- Stock Information
- Founded
- EIC N/A
- CDXC 1999
- Country
- EIC United States
- CDXC United States
- Employees
- EIC N/A
- CDXC N/A
- Industry
- EIC Finance/Investors Services
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- EIC Finance
- CDXC Health Care
- Exchange
- EIC Nasdaq
- CDXC Nasdaq
- Market Cap
- EIC 250.6M
- CDXC 264.4M
- IPO Year
- EIC 2019
- CDXC N/A
- Fundamental
- Price
- EIC $16.46
- CDXC $6.50
- Analyst Decision
- EIC
- CDXC Strong Buy
- Analyst Count
- EIC 0
- CDXC 2
- Target Price
- EIC N/A
- CDXC $8.00
- AVG Volume (30 Days)
- EIC 116.0K
- CDXC 2.5M
- Earning Date
- EIC 11-14-2023
- CDXC 10-31-2024
- Dividend Yield
- EIC 13.63%
- CDXC N/A
- EPS Growth
- EIC N/A
- CDXC N/A
- EPS
- EIC 0.80
- CDXC 0.02
- Revenue
- EIC N/A
- CDXC $91,668,000.00
- Revenue This Year
- EIC N/A
- CDXC $15.33
- Revenue Next Year
- EIC N/A
- CDXC $20.08
- P/E Ratio
- EIC $20.31
- CDXC $326.79
- Revenue Growth
- EIC N/A
- CDXC 9.95
- 52 Week Low
- EIC $13.00
- CDXC $1.32
- 52 Week High
- EIC $16.48
- CDXC $7.08
- Technical
- Relative Strength Index (RSI)
- EIC 61.21
- CDXC 76.86
- Support Level
- EIC $15.88
- CDXC $3.39
- Resistance Level
- EIC $16.30
- CDXC $7.08
- Average True Range (ATR)
- EIC 0.25
- CDXC 0.47
- MACD
- EIC 0.06
- CDXC 0.34
- Stochastic Oscillator
- EIC 79.75
- CDXC 84.28
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.